Telomere length at diagnosis of chronic phase chronic myeloid leukemia (CML-CP) identifies a subgroup with favourable prognostic parameters and molecular response according to the ELN criteria after 12 months of treatment with nilotinib

Wenn, K.; Lange, T.; Brümmendorf, Tim Henrik; Ziegler, Patrick; Koschmieder, Steffen; Hochhaus, A.; Wilop, S.; Giles, F. J.; Hasenbank, C.; Frank, O.; Tomala, L.; Vankann, L.; Beier, F.; Müller, M. C.

doi:1476-5551

Information
References (0)
Discussion (0)
Files

Telomere length at diagnosis of chronic phase chronic myeloid leukemia (CML-CP) identifies a subgroup with favourable prognostic parameters and molecular response according to the ELN criteria after 12 months of treatment with nilotinib - RWTH-CONV-092106

Similar records

h1

h2

h3

h4

h5

h6

RWTH

Kontakt

RWTH Publications

Allgemeines